ENDOCYTE
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal and ovarian cancer; EC145, a folate-targeted chemotherapeutic conjugate to treat various tumors, including cancers of the breast, lung, and blood; EC0225, a targeted chemotherapy drug; BMS753493, a folate-targeted anti-cancer therapy drug; EC0434 to target folate recept... or positive tumors; and EC0305, an anti-cancer therapy drug. It also offers EC0286, a folate-targeted small molecule for the treatment of inflammatory diseases; and EC20, a folate-targeted radiopharmaceutical imaging agent to identify folate-receptor positive cancers. The company was founded in 1996 and is based in West Lafayette, Indiana.
ENDOCYTE
Industry:
Biotechnology Health Care Pharmaceutical
Founded:
1996-01-01
Address:
West Lafayette, Indiana, United States
Country:
United States
Website Url:
http://www.endocyte.com
Total Employee:
51+
Status:
Active
Contact:
(765) 463-7175
Email Addresses:
[email protected]
Total Funding:
114.35 M USD
Technology used in webpage:
SPF Domain Not Resolving Microsoft Exchange Online Amazon Office 365 Mail DMARC Vimeo AWS Global Accelerator Barracuda Networks Akamai DNS
Similar Organizations
Apogenix
Apogenix is a biopharmaceutical company developing novel protein therapeutics for the treatment of cancer and inflammatory diseases.
Oncotelic Therapeutics
Oncotelic is a biopharmaceutical company, develops anti-vascular therapeutics for patients with cancer and sight-threatening eye diseases.
Soligenix
Soligenix is a biopharmaceutical company that develops biodefense vaccines and therapeutics to treat rare diseases.
Current Advisors List
Current Employees Featured
Founder
Stock Details
Investors List
MidCap Financial
MidCap Financial investment in Venture Round - Endocyte
Silicon Valley Bank
Silicon Valley Bank investment in Venture Round - Endocyte
Burrill & Company
Burrill & Company investment in Series C - Endocyte
Sanderling Ventures
Sanderling Ventures investment in Series C - Endocyte
Triathlon Medical Venture Partners
Triathlon Medical Venture Partners investment in Series C - Endocyte
Blue Chip Venture Company
Blue Chip Venture Company investment in Series C - Endocyte
Indiana University Health
Indiana University Health investment in Series C - Endocyte
American Bailey Ventures
American Bailey Ventures investment in Series C - Endocyte
American Bailey Ventures
American Bailey Ventures investment in Series C - Endocyte
CID Capital
CID Capital investment in Series C - Endocyte
Official Site Inspections
http://www.endocyte.com
- Host name: 104.18.4.189
- IP address: 104.18.4.189
- Location: United States
- Latitude: 37.751
- Longitude: -97.822
- Timezone: America/Chicago
More informations about "Endocyte"
Endocyte - Wikipedia
Endocyte is a biopharmaceutical company established in 1996 and headquartered in West Lafayette, Indiana, a resident of the Purdue Research Park. In 2011 the company completed successfully an initial public offering (IPO). As of 2013 , the company had 93 employees. The original president and CEO, Ron Ellis, was succeeded by Mike Sherman, who held a CFO position at the company before this change in June 2016. In 2018 the company was acquired by Novartis. See details»
Novartis announces planned acquisition of Endocyte to expand …
Oct 18, 2018 This offer values Endocyte's equity at USD 2.1 billion. Closing of the transaction is subject to customary closing conditions, including the approval of Endocyte's stockholders and …See details»
Endocyte - Crunchbase Company Profile & Funding
Endocyte, Inc., a biopharmaceutical company, develops receptor-targeted therapeutics to treat cancer and autoimmune/inflammatory diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat …See details»
Endocyte, Inc. - Drug pipelines, Patents, Clinical trials - Synapse
Explore Endocyte, Inc. with its drug pipeline, therapeutic area, technology platform, 36 clinical trials, 49 news, and 182 literature, Disease Domain:Neoplasms, Nervous System Diseases, …See details»
Novartis successfully completes acquisition of Endocyte
Basel, December 21, 2018 - Novartis today announced that it has completed the acquisition of Endocyte, Inc., a US-based biopharmaceutical company focused on developing radioligand …See details»
Endocyte Company Profile 2024: Valuation, Investors, …
Endocyte General Information Description. Developer of receptor-targeted therapeutics for the treatment of cancer and autoimmune diseases. The company provides EC17, a folate-targeted hapten therapy drug to treat metastatic renal …See details»
Novartis buys Endocyte for $2.1B in latest deal under CEO …
Oct 18, 2018 Dive Brief: Novartis will buy the Indiana-based biotech Endocyte and its experimental radiopharmaceutical drug for $2.1 billion, the Swiss pharma announced …See details»
Endocyte - Funding, Financials, Valuation & Investors - Crunchbase
Endocyte is registered under the ticker NASDAQ:ECYT . Their stock opened with $6.00 in its Feb 4, 2011 IPO. Stock Symbol NASDAQ:ECYT ; Money Raised at IPO $101.8M; IPO Share Price …See details»
Novartis to acquire Endocyte in $2.1bn deal - Financial …
Oct 18, 2018 Novartis is paying $24 a share — a 54 per cent premium over Wednesday’s closing price — valuing Endocyte’s equity at $2.1bn. Vas Narasimhan, who took over as Novartis’s chief executive ...See details»
Endocyte - Contacts, Employees, Board Members, Advisors & Alumni
Endocyte is a biopharmaceutical company that develops receptor-targeted therapeutics to treat cancer and inflammatory diseases. ... Solutions. Products. Resources. Pricing. Resources. …See details»
Novartis to acquire US cancer drug developer Endocyte …
Swiss pharmaceutical firm Novartis has signed a $2.1bn deal to purchase all outstanding shares of US-based biopharmaceutical company Endocyte in order to bolster its position in radiopharmaceuticals. Founded in 1996, Endocyte …See details»
Endocyte Company Profile - Office Locations, Competitors ... - Craft
Endocyte is a biopharmaceutical company and leader in developing targeted therapies for the treatment of cancer and other serious diseases. It uses its proprietary drug conjugation …See details»
Endocyte becomes first Purdue startup to reach $1.5B in value
Oct 3, 2018 A turning point for Endocyte came in the fall of 2017 when the company obtained exclusive worldwide rights from a Germany company to develop and commercialize Lu-PSMA …See details»
Why We Did What We Did: PSMA PET/CT Selection Criteria for the …
Endocyte was founded in 1996 to develop small-molecule drug conjugates and imaging agents targeting the folate receptor . In 2012, Endocyte entered into a license agreement with Merck …See details»
Merck and Endocyte Enter Exclusive Worldwide Agreement to …
Apr 16, 2012 Merck, known as MSD outside the United States and Canada, (NYSE: MRK) and Endocyte Inc. (NASDAQ: ECYT), today announced that they have entered into an agreement …See details»
Endocyte: A Promising Prospect In The Oncology Space - Seeking …
Jun 18, 2015 Endocyte has two more folate receptor-targeted SMDCs, EC1669 and EC0371. Both, EC1669 and EC0371, are also in pre-clinical development. Sufficient Cash To Develop …See details»
Endocyte: Elucidating The Investment Thesis Of A Stellar Cancer ...
Jun 15, 2018 Endocyte is powering a highly valuable pipeline of precision medicines for difficult-to-treat cancers. With the strong Phase 2 data, the FDA recommended the company to …See details»
Why We Did What We Did: PSMA-PET/CT Selection Criteria for the …
Endocyte: A Phoenix Risen from the Ashes Endocyte was founded in 1996 to develop small molecule drug conjugates (SMDCs) and imaging agents targeting the folate receptor1. In …See details»
Endocytosis in the context-dependent regulation of individual and ...
Jun 1, 2021 Tissue organization by mechanosensitive membrane trafficking. At variance with apical–basal cell polarity, planar cell polarity is a system of information that provides cues …See details»
The endocytic pathway: a mosaic of domains - Nature
Oct 1, 2001 The early endosome is a dynamic compartment with a high homotypic fusion capacity 1.But its elements display a highly complex and pleiomorphic organization that …See details»